Format

Send to

Choose Destination
J Clin Oncol. 2011 Feb 10;29(5):532-43. doi: 10.1200/JCO.2010.30.1382. Epub 2011 Jan 10.

Modern therapy of acute lymphoblastic leukemia.

Author information

1
Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy. rbassan@ospedaliriuniti.bergamo.it

Abstract

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics. These data, along with the kinetics of response to early treatment, help establish the individual risk class with considerable accuracy, and support risk-specific treatments that should warrant optimal results with as little as possible nonrelapse mortality. Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy, all integrated with the analysis of prognostic factors and the study of subclinical residual disease for key therapeutic decisions. These changes are improving long-term outcome, which in ongoing studies is expected close to 50% or greater.

PMID:
21220592
DOI:
10.1200/JCO.2010.30.1382
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center